Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Telix Pharmaceuticals Ltd banner

Telix Pharmaceuticals Ltd
F:T3X

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
F:T3X
Watchlist
Price: 10.708 EUR -0.39%
Market Cap: €3.6B
Write Note Create Alert Ask AI

Wall St Price Targets

T3X Price Targets Summary
Telix Pharmaceuticals Ltd

Wall Street analysts forecast T3X stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for T3X is 12.859 EUR with a low forecast of 10.997 EUR and a high forecast of 18.653 EUR.

T3X Lowest Forecast
Wall Street Target
€10.997
3% Upside
T3X Average Forecast
Wall Street Target
€12.859
20% Upside
T3X Highest Forecast
Wall Street Target
€18.653
74% Upside
Lowest Forecast
Price Target
10.997 EUR
3% Upside
Average Forecast
Price Target
12.859 EUR
20% Upside
Highest Forecast
Price Target
18.653 EUR
74% Upside
Telix Pharmaceuticals Ltd Competitors:
Price Targets

Revenue
Forecast

228% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
228% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 7 years, the compound annual growth rate for Revenue has been 228%. The projected CAGR for the next 8 years is 12%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss
N/A
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss

The compound annual growth rate for Gross Profit over the next 8 years is 16%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
38%
Average Beat
N/A
Past Growth
41% / Year
Estimated Growth
Estimates Accuracy
38%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 41%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
30%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
30%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
25%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
25%
Average Beat

What are analyst estimates?

Continue T3X Research

Summary
T3X intrinsic value, competitors valuation, and company profile.
DCF Valuation
T3X stock valuation using Discount Cash Flow valuation method.
Relative Valuation
T3X stock valuation using valuation multiples.
Wall St Estimates
T3X price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
T3X stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Telix Pharmaceuticals Ltd listings:
OTC • USD
TLPPF
 ASX • AUD
TLX
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is T3X's stock price target?
Price Target
12.859 EUR

According to Wall Street analysts, the average 1-year price target for T3X is 12.859 EUR with a low forecast of 10.997 EUR and a high forecast of 18.653 EUR.

What is the Revenue forecast for Telix Pharmaceuticals Ltd?
Projected CAGR
12%

Over the last 7 years, the compound annual growth rate for Revenue has been 228%. The projected CAGR for the next 8 years is 12%.

What is the Gross Profit forecast for Telix Pharmaceuticals Ltd?
Projected CAGR
16%

The compound annual growth rate for Gross Profit over the next 8 years is 16%.

What is the Operating Income forecast for Telix Pharmaceuticals Ltd?
Projected CAGR
41%

The compound annual growth rate for Operating Income over the next 8 years is 41%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.